Skip to main content

Table 2 Comparison in efficacy between RCA and heparin anticoagulation for IHD

From: Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study

Variables

Before inverse probability of treatment weighting

After inverse probability of treatment weighting

IHD sessions with RCA (n = 124)

IHD sessions with heparin (n = 84)

p-value

IHD sessions with RCA (n = 112)

IHD sessions with heparin (n = 82)

p-value

|d|

Prescribed duration, min

271 ± 92

252 ± 59

0.35

271 ± 94

251 ± 57

0.07

0.250

Delivered duration, min

225 ± 84

234 ± 70

0.32

228 ± 78

229 ± 71

0.91

0.017

Difference between prescribed and delivered duration, min

45 ± 97

18 ± 50

0.01

43 ± 97

22 ± 56

0.07

0.262

Prescribed blood flow, mL/min

237 ± 39

257 ± 33

0.02

243 ± 40

254 ± 31

0.06

0.296

Delivered blood flow, mL/min

232 ± 36

245 ± 31

0.11

237 ± 37

236 ± 30

0.82

0.037

Difference between prescribed and delivered blood flow, mL/min

5 ± 19

12 ± 26

0.04

6 ± 18

18 ± 28

0.003

0.533

Prescribed dialysate flow, mL/min

481 ± 59

490 ± 46

0.43

488 ± 57

484 ± 52

0.70

0.070

Delivered dialysate flow, mL/min

485 ± 52

488 ± 50

0.81

490 ± 54

482 ± 57

0.39

0.159

Prescribed ultrafiltration, L

1.19 ± 0.98

1.30 ± 0.97

0.71

1.22 ± 0.99

1.20 ± 0.98

0.92

0.016

Net ultrafiltration at the end of session, L

0.96 ± 0.92

1.13 ± 0.91

0.33

1.02 ± 0.91

1.03 ± 0.94

0.93

0.015

Difference between prescribed and net ultrafiltration, L

0.23 ± 0.51

0.17 ± 0.34

0.34

0.20 ± 0.48

0.17 ± 0.35

0.65

0.069

Kt/V per hour

0.247 ± 0.068

0.227 ± 0.063

0.08

0.243 ± 0.072

0.217 ± 0.063

0.02

0.392

Kt/V at the end of session

0.95 ± 0.38

0.89 ± 0.32

0.98

0.93 ± 0.38

0.84 ± 0.32

0.61

0.242

Kt at the end of session

33.2 ± 13.4

34.5 ± 12.7

0.58

33.7 ± 13.5

32.0 ± 12.6

0.42

0.126

Kt/V at the end of session in 2015

0.97 ± 0.37

0.86 ± 0.30

0.53

NE

NE

  

Kt/V at the end of session in 2017

0.91 ± 0.41

0.92 ± 0.33

0.51

NE

NE

  

Kt at the end of session in 2015

31.9 ± 10.9

31.1 ± 10.3

0.80

NE

NE

  

Kt at the end of session in 2017

35.0 ± 16.1

37.3 ± 13.9

0.54

NE

NE

  
  1. NE not evaluated (Inverse probability of treatment weighting was not applied to the subgroup analyses in 2015 and 2017), RCA regional citrate anticoagulation, IHD intermittent hemodialysis